How can we compose a large‑scale compound prescription with promising curative effects? Are there accessible formulation‑making principles for constructing such prescriptions?

 

The fundamental principle behind traditional‑Chinese‑medicine prescription‑making lies in herb compatibility based on the seven‑interrelationship theory of medicinal herbs, which was first recorded in Shen‑nong’s Classic of Materia Medica. The so‑called seven‑interrelationships refer to seven types of interactions between Chinese medicinal materials, namely: solo application, mutual reinforcement, mutual assistance, mutual restraint, mutual suppression, mutual inhibition and mutual antagonism.

 

Solo‑application means a single herb exerts therapeutic effects independently without assistance from other ingredients. Plenty of single‑herb prescriptions exist in traditional Chinese medicine. Examples include Ginseng Decoction for replenishing primordial qi, Dushen Powder made of pollen typhae for hemostasis, and Licorice Decoction for sore throats.

 

Mutual reinforcement describes the combined use of two herbs with similar medicinal properties to amplify their respective effects. For instance, the pairing of ephedra and cassia twig strengthens sweat‑inducing and exterior‑releasing effects; gypsum combined with anemarrhena enhances heat‑clearing and fire‑draining performance.

 

Mutual assistance follows a primary‑auxiliary structure: one herb acts as the main ingredient while the other serves as an adjuvant that boosts the principal herb’s efficacy. Astragalus is commonly assisted by poria cocos, which improves astragalus’s capacity to replenish qi and promote diuresis.

 

Mutual restraint occurs when the toxic and side‑effects of one herb are curbed by another. Fresh ginger reduces the toxicity of pinellia tuber and monkshood root, and honey detoxifies aconitum. This relationship is summed up as pinellia tuber being restrained by fresh ginger and aconitum restrained by honey.

 

Mutual suppression means one medicinal herb can neutralise the toxicity of another. Mutual restraint and mutual‑suppression represent a bidirectional interaction: pinellia tuber being restrained by ginger equals ginger suppressing the toxicity of pinellia tuber.

 

Mutual inhibition takes place when two herbs are administered together and one weakens the original medicinal power of the other. Radish seed carries strong diuretic properties, speeds up the metabolism of ginseng inside the human body and weakens ginseng’s qi‑tonifying effect. Radish‑seed should therefore generally be avoided alongside ginseng‑based qi‑replenishing therapy.Nevertheless, mutually‑inhibitive herbs are capable of alleviating drug‑induced adverse reactions. When ginseng overuse syndrome develops after ginseng intake, marked by high fever, constipation, flushing, irritability and restlessness, radish‑seed or raw radish can rapidly ease such symptoms.

Mutual antagonism refers to incompatible herb pairs that produce severe toxicity and harmful side‑effects after joint administration. The Eighteen Antagonistic Medicinal Pairs and Nineteen Restrained Herb Combinations are classic compatibility taboos in traditional Chinese medicine.From a modern perspective, several of these ancient prohibitions lack scientific backing and stem purely from primitive speculation. One outdated fallacy held that white‑coloured herbs conflicted against black‑coloured ones owing to the supposed opposition between water and fire, an utterly unreasonable assumption.Meanwhile, generations of TCM practitioners have uncovered other toxic herb combinations excluded from the classic eighteen antagonistic pairs. The combined use of corydalis and nux vomica, for example, amplifies toxicity. I have previously published a lengthy paper sorting out knowledge on herbal toxicity and addressing this subject in depth, which interested readers may look up among my earlier writings. No further elaboration will be provided here.

 

In summary: herb pairs characterised by mutual reinforcement and mutual assistance are adopted to strengthen therapeutic outcomes; herbs linked by mutual restraint and mutual‑suppression are deployed to reduce medicinal toxicity.

 

Though mutually‑inhibitive herbs seldom trigger serious adverse reactions, they weaken curative potency and should be kept to a minimum. They may only be prescribed deliberately to counteract drug‑related side‑effects. Mutually‑antagonistic medicinal materials are strictly forbidden in compatibility.

 

Viewed in the present‑day context, these ancient compatibility guidelines constitute rational principles for herb matching. Both traditional‑Chinese‑medicine herbs and Western pharmaceuticals still largely abide by these compatibility rules for combined medication.

 

Fundamentally, large‑scale compound prescriptions ought to comply with the above‑mentioned rules. Yet the more types of herbs a formula incorporates, the harder these principles become to implement. Medicinal actions, adverse reactions and complex interactions between ingredients grow increasingly intricate. That explains why large‑scale compound prescriptions have long drawn criticism from numerous clinicians.

 

As I noted in my prior essays, intricate illnesses cannot be resolved through oversimplified modes of thinking. When treating patients with complicated aetiologies and pathological conditions, practitioners need to address every contributing cause comprehensively. Formulas with too few ingredients fail to tackle the full spectrum of health issues troubling the patient.

 

Multiple pathological concerns interact with one another. If only one symptom gets treated while others remain unaddressed, the resolved ailment will relapse once medication stops, triggered by lingering underlying disorders, rendering all prior treatment fruitless.

 

Large‑scale compound prescriptions accordingly serve as a viable treatment strategy for intractable diseases. Only by tackling interrelated pathological problems concurrently can clinicians deliver comprehensive treatment, lower the risk of symptom rebound and disease recurrence.

 

Such elaborate formulas are unnecessary for straightforward, mild ailments. For common minor complaints, I tend to prescribe single‑herb remedies or compact small‑scale formulas containing merely several ingredients. These compact prescriptions feature simple compatibility structures and mostly manage self‑limiting conditions.

 

Occasionally, small formulas succeed in curing isolated cases of stubborn diseases. Still, stable, replicable therapeutic results cannot be guaranteed, and their overall response rate stays low. Reliance on narrow formulas for intractable illnesses easily wastes patients’ precious treatment window.

 

I first created large‑scale prescriptions by merging multiple proven‑effective small formulas. My initial reasoning was straightforward: if one promising formula carries a 1‑percent success rate, two combined formulas might achieve 2‑percent therapeutic odds. My clinical observations have validated that additive curative benefits do emerge on certain occasions.

 

My potent anti‑emetic prescription, whose recipe has been released in my earlier articles and will be revisited in my subsequent thematic chapters, merges well‑known anti‑vomiting formulas including Xuan‑fu‑Dai‑zhe Decoction, Er‑chen Decoction, Ju‑pi‑Zhu‑ru Decoction and Ding‑xiang‑Shi‑di Powder. This compound outperforms most common anti‑emetic medications when controlling intractable chemotherapy‑induced nausea and vomiting.

 

This seemingly crude method proves remarkably efficient. These time‑tested ancient formulas have had their therapeutic value validated across countless clinical cases. Since herb‑to‑herb combination yields synergistic benefits, it logically follows that formula‑to‑formula merging can likewise enhance efficacy.

 

Many practitioners argue that multi‑ingredient large‑scale formulas trigger chemical reactions between constituents. While this possibility exists, modern‑day chemical research reveals each single Chinese‑medicinal herb contains hundreds, sometimes over a thousand distinct chemical components. Even compact small‑scale formulas made up of a handful of herbs generate intricate chemical interactions after blending. Large‑scale formulas merely carry marginally higher reaction risks.

 

Biochemical knowledge further demonstrates that biochemical reactions do not readily take place. Most reactions require enzymatic catalysis. Enzymatic reactions feature strict substrate specificity and exacting reaction prerequisites. Hence the practical risks associated with multi‑herb medication are far lower than commonly assumed.

 

We may treat an established compact formula as a single complex‑composition herb. Merging multiple formulas follows the exact same seven‑interrelationship compatibility rules governing individual herbs: solo application, mutual reinforcement, mutual assistance, mutual restraint, mutual suppression, mutual inhibition and mutual antagonism.

 

Beyond the seven‑interrelationship theory, another classic TCM formulation framework distinguishes monarch, minister, assistant and guide herbs. Personally, I recommend practitioners grasp its core rationale instead of rigidly conforming to its old‑fashioned rigid restrictions.

 

The monarch‑minister‑assistant‑guide framework shares core logic with the seven‑interrelationship theory and essentially offers alternative terminology. Successive generations of scholars, however, burdened this framework with inflexible, irrational regulations. Su‑wen (Plain Questions) records the rule: “One monarch herb paired with two minister herbs constitutes a minor‑sized prescription; one monarch, three minister and five assistant herbs form a medium‑sized prescription; one monarch, three minister and nine assistant herbs compose a major‑sized prescription.”Such numeric constraints amount to pointless wordplay and numerical games that severely restrict clinicians’ flexible medication‑making thinking.

 

I intend to illustrate my multi‑target large‑compound prescription philosophy through modern mathematical logic. Readers are reminded not to treat these concepts as inflexible dogmas. Instead, they ought to absorb this mode of thinking and tailor clinical strategies to real‑world conditions.

 

Middle‑school‑level algebraic concepts of like terms and factors help illustrate multi‑target formulation logic. Similar‑function formulas operate as like terms that can be combined to resolve one category of patient complaint.

 

For example, multiple historical ascites‑targeted empirical formulas can be grouped as like‑terms for advanced‑stage cancer‑related abdominal dropsy.

 

Distinct‑function formulas that all benefit one patient act as separate algebraic factors capable of multiplicative‑style combination. Advanced‑stage cancer patients frequently endure ascites, cancer‑triggered pain and tumour‑related fever. Anti‑ascites formulas are grouped as one set of like terms, analgesic formulas form a second group, and anti‑fever prescriptions constitute the third. These three groups are then combined like multiplied algebraic factors.

 

With basic junior‑high‑school mathematics knowledge, readers can readily comprehend this multi‑target compatibility strategy. My mathematical analogy is not a forced fusion of mathematics and traditional Chinese medicine; it serves to simplify the understanding of my formulation‑building mindset.

 

Mathematics and medicine belong to separate disciplinary spheres with overlapping traits and fundamental disparities. Clinical medicine prioritises practical experience. This chapter adopts inductive‑deductive reasoning. Conclusions derived from such reasoning remain provisional and demand verification through animal trials and human clinical practice.

 

Statistical data underpins practical validation. I therefore advocate combining this multi‑target formulation method with animal experiments to test its efficacy and safety. Safe clinical application begins with identifying high‑efficiency protocols via laboratory animal research. Regrettably, most TCM practitioners lack access to such experimental resources.

 

Controlled trials represent another viable research approach for multi‑target medication protocols. Over years of clinical practice, I adopted controlled research to continuously optimise my large‑scale multi‑target compound formulas.

 

I would prepare Prescription A and Prescription B, with B containing one extra herb or herbal group added to Prescription A. Comparable patients were split into two groups receiving A and B separately. Whenever B outperformed A, I prioritised B for all subsequent patients. I then developed Prescription C by adding another herb set to B. I kept updating optimal prescriptions by comparing therapeutic responses, repeating this cycle for roughly ten years.

 

Fellow practitioners adopting multi‑target large‑compound therapy ought to refine their formulas iteratively to boost medication safety and curative effectiveness. Laboratory‑based animal trials would accelerate the discovery of superior protocols. Research of this scale requires state‑funded projects and large‑scale research institutes. Whether such opportunities emerge in the future remains uncertain.